Vifor Pharma appoints heads of International Business Operations and Global Marketing
Vifor Pharma today announced the appointments of Dario Eklund as Head of International Business Operations (including North America) and Abdul Mullick as Head of Global Marketing. Both positions will report directly to the CEO of Vifor Pharma Søren Tulstrup and will be based at the headquarters in Zurich, Switzerland.
Dario Eklund joins Vifor Pharma from Organogenesis Inc. in Boston, USA, where he was Vice President with responsibility for non-US operations, business development and licensing and the Gintuit business unit. Prior to that, Mr. Eklund was General Manager of Aventis Pharma (now Sanofi) in Switzerland, which he joined after several roles of increasing responsibility, such as Commercial Director, Area Manager Eastern Europe & Israel and Country Manager, at Novartis in Basel. Mr. Eklund holds a master's degree from the Swedish School of Economics and Business Administration in Helsinki, Finland.
Abdul Mullick was most recently Vice President and General Manager, endocrinology and cardiology, in the rare diseases division of Sanofi (formerly Genzyme) in Boston, where he led the US and international operations; and prior to this, he was responsible for global marketing for rare genetic diseases. Before moving to Boston, he spent several years with Genzyme in Europe where he led the endocrine and renal business unit in the Asia-Pacific region and the endocrine business unit in Europe. Before joining Genzyme, Mr. Mullick held a number of positions at Novartis, including Senior Global Brand Lead with responsibility for the diabetes franchise. Mr. Mullick has a Ph.D. in molecular biology from Bristol, England.
For further information, please contact:
Media Relations:
Beatrix Benz, Head of Global Communications
Tel.: +41 58 851 80 16
E-mail: communications@viforpharma.com
Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.
For more information about Vifor Pharma and its parent company Galenica, please visit www.viforpharma.com and www.galenica.com.
Press Release (PDF)